A cutting-edge federated technology-powered network known as TriNetX powered an impressive real-world evidence study involving approximately 400 million patients across 30 countries. Based on a federated, distributed model the system pulls electronic medical records—that is from diagnoses and procedures to medications and more—in an aggregated format supporting deep analytics of the de-identified patient data. American and German researchers represent the University of Virginia at Charlottesville and Charité–Universitätsmedizin Berlin analyzed a cohort of 22,560 COVID-19 patients receiving H1/H2 receptor antagonists, with a special focus on 1,379 severe cases requiring respiratory support. Establishing mortality as a primary endpoint the researchers explained they hoped to mitigate cofounder by employing propensity-score matching with a goal of “stratified and balanced sub-cohorts across age and gender.” What they found was stunning. Among other benefits famotidine provided what the authors declared was “an immense benefit” to COVID-19 patients.
Known for its trade name Pepcid, this drug is a histamine H receptor antagonist medication reducing...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).